ArticleMolecular neurobiology2025
Differential Expression of Disulfidptosis-Related Genes in Spinal Cord Injury and Their Role in the Immune Microenvironment.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Disulfidptosis: Mechanisms, evidence boundaries, and translational opportunities.Redox biology · 2026Review
- Mitochondrial-Inflammatory Axis Dysregulation Triggers Disulfidptosis and the Multifaceted Protective Mechanism of Bisphenol A Following Spinal Cord Injury.Molecular neurobiology · 2026Article
- Adipose tissue-derived stromal cells enhance glycolytic metabolism in injured nerve cells via the FOXK1-HK2 axis for spinal cord injury repair.Journal of translational medicine · 2026Article
- Identification of genes associated with disulfidptosis in the subacute phase of spinal cord injury and analysis of potential therapeutic targets.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Spinal cord injury (SCI) often results in severe sensory, motor, and autonomic dysfunction, with limited treatment options due to complex underlying mechanisms. Disulfidptosis, a recently discovered form of cell death driven by disulfide bond accumulation, has been linked to various diseases, but its role in SCI remains unexplored. This study investigates the involvement of disulfidptosis-related genes (DRGs) in SCI to identify potential diagnostic markers and therapeutic targets. Using SCI datasets from the Gene Expression Omnibus (GEO), we conducted differential gene expression analysis, identifying key disulfidptosis-related differentially expressed genes (DRDEGs). Further analysis through gene set enrichment (GSEA) and Bayesian pathway enrichment highlighted significant involvement in pathways such as NF-κB, PI3K/Akt, and MAPK, with an emphasis on nephrin family interactions. Three core DRDEGs-HK2, Map3k8, and S100a6-were identified, and a diagnostic model built on these genes demonstrated strong predictive performance (AUC: 0.896 in training, 0.850 in validation). Additionally, real-time PCR (qRT-PCR) in an animal model validated the elevated expression of these DRDEGs in SCI samples. This research provides novel insights into disulfidptosis in SCI, suggesting these genes as promising targets for improved diagnostic and therapeutic strategies.
Indexed as
Identifiers
40237950What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.